For: | Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J, Group TKULDS. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16(35): 4400-4409 [PMID: 20845506 DOI: 10.3748/wjg.v16.i35.4400] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i35/4400.htm |
Number | Citing Articles |
1 |
Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Journal of Hepatology 2013; 59(2): 205 doi: 10.1016/j.jhep.2013.03.020
|
2 |
Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lung Yu. Chronic hepatitis C infection in the elderly. The Kaohsiung Journal of Medical Sciences 2011; 27(12): 533 doi: 10.1016/j.kjms.2011.10.020
|
3 |
Masahiro Takita, Satoru Hagiwara, Masatoshi Kudo, Masashi Kouno, Hirokazu Chishina, Tadaaki Arizumi, Satoshi Kitai, Norihisa Yada, Tatsuo Inoue, Yasunori Minami, Kazuomi Ueshima. Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus. Oncology 2014; 87(Suppl. 1): 110 doi: 10.1159/000368154
|
4 |
H. Zhou, H. Luo, S. Xiao, H. Wang, G. Gong. Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis. European Journal of Clinical Microbiology & Infectious Diseases 2014; 33(4): 491 doi: 10.1007/s10096-013-1992-8
|
5 |
PN Rao, Abraham Koshy, Jacob Philip, Narayanan Premaletha, Joy Varghese, Krishnasamy Narayanasamy, Samir Mohindra, Nitin Vikas Pai, Manoj Kumar Agarwal, Ashoknanda Konar, Hasmukh B Vora. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World Journal of Hepatology 2014; 6(7): 520-526 doi: 10.4254/wjh.v6.i7.520
|
6 |
Zongguo Yang, Liping Zhuang, Lei Yang, Cheng Liu, Yunfei Lu, Qingnian Xu, Xiaorong Chen, Liang Chen. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2014; 38(4): 440 doi: 10.1016/j.clinre.2013.08.013
|
7 |
Hatsue Fujino, Michio Imamura, Yuko Nagaoki, Yoshiiku Kawakami, Hiromi Abe, C. Nelson Hayes, Hiromi Kan, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Youji Honda, Noriaki Naeshiro, Ayako Urabe, Satoe Yokoyama, Daisuke Miyaki, Eisuke Murakami, Tomokazu Kawaoka, Nobuhiko Hiraga, Masataka Tsuge, Akira Hiramatsu, Hideyuki Hyogo, Hiroshi Aikata, Shoichi Takahashi, Daiki Miki, Hidenori Ochi, Waka Ohishi, Kazuaki Chayama. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. Journal of Gastroenterology 2014; 49(12): 1548 doi: 10.1007/s00535-013-0924-9
|
8 |
N. Furusyo, M. Murata, E. Ogawa, K. Toyoda, T. Ihara, H. Ikezaki, T. Hayashi, T. Koga, M. Kainuma, J. Hayashi. Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Journal of Antimicrobial Chemotherapy 2011; 66(5): 1127 doi: 10.1093/jac/dkr034
|
9 |
Saad S. Alkhowaiter, John C.T. Wong, Eric M. Yoshida. Hepatology highlights. Annals of Hepatology 2013; 12(3): 354 doi: 10.1016/S1665-2681(19)30996-2
|
10 |
Hideyuki Nomura, Yuugou Miyagi, Hironori Tanimoto, Nobuyuki Yamashita, Seiji Oohashi, Saburo Nishiura. Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin. Hepatology Research 2012; 42(3): 241 doi: 10.1111/j.1872-034X.2011.00930.x
|
11 |
In Hee Kim, Tatiana Kisseleva, David A. Brenner. Aging and liver disease. Current Opinion in Gastroenterology 2015; 31(3): 184 doi: 10.1097/MOG.0000000000000176
|
12 |
Hiroshi Isoda, Satoshi Oeda, Ayako Takamori, Keiko Sato, Michiaki Okada, Shinji Iwane, Hirokazu Takahashi, Keizo Anzai, Yuichiro Eguchi, Kazuma Fujimoto. Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects. Internal Medicine 2020; 59(2): 169 doi: 10.2169/internalmedicine.3248-19
|
13 |
MOTOYUKI KOHJIMA, MIHO KUROKAWA, MUNECHIKA ENJOJI, TSUYOSHI YOSHIMOTO, TSUKASA NAKAMURA, TOMOKO OHASHI, KUNITAKA FUKUIZUMI, NAOHIKO HARADA, YUSUKE MURATA, KAZUHISA MATSUNAGA, MASAKI KATO, KAZUHIRO KOTOH, MAKOTO NAKAMUTA. Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C. Experimental and Therapeutic Medicine 2016; 11(5): 1781 doi: 10.3892/etm.2016.3133
|
14 |
Hyeong Il Kim, In Hee Kim, Byung Jun Jeon, Seok Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim. Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea. Hepatitis Monthly 2012; 12(7): 430 doi: 10.5812/hepatmon.6170
|
15 |
Stephen Malnick, Yaakov Maor, Ehud Melzer, Sari Tal. Chronic Hepatitis C in the Aged: Much Ado About Nothing or Nothing to Do?. Drugs & Aging 2014; 31(5): 339 doi: 10.1007/s40266-014-0170-8
|
16 |
Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy 2011; 17(6): 737 doi: 10.1007/s10156-011-0249-7
|
17 |
C.‐C. Hu, C.‐L. Lin, Y.‐L. Kuo, C.‐H. Chien, S.‐W. Chen, C.‐L. Yen, C.‐Y. Lin, R.‐N. Chien. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2013; 37(1): 81 doi: 10.1111/apt.12112
|
18 |
Hiroshi Kohno, Hirotaka Kouno, Shiomi Aimitsu, Yasuyuki Aisaka, Mikiya Kitamoto, Hiroiku Kawakami, Kazuaki Chayama. Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads. Hepatology Research 2011; 41(7): 626 doi: 10.1111/j.1872-034X.2011.00811.x
|
19 |
Shinji Shimoda, Kosuke Sumida, Sho Iwasaka, Satomi Hisamoto, Hironori Tanimoto, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Akira Kawano, Eiichi Ogawa, Norihiro Furusyo, Koichi Akashi, Jun Hayashi. Interferon-α-Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections. Hepatitis Research and Treatment 2013; 2013: 1 doi: 10.1155/2013/374196
|
20 |
Takashi Goto, Shigetoshi Ohshima, Kouichi Miura, Tomomi Shibuya, Wataru Sato, Takahiro Dohmen, Kentaro Kamada, Ryo Kanata, Toshitaka Sakai, Mitsuru Chiba, Yuko Sugimoto, Shinichiro Minami, Hirohide Ohnishi. A Chronic Subdural Hematoma in a Patient Receiving Combination Therapy with Pegylated Interferon Alfa-2b and Ribavirin for Chronic Hepatitis C. Internal Medicine 2013; 52(18): 2057 doi: 10.2169/internalmedicine.52.0791
|
21 |
Ivonete Silva, Roberto Carvalho Filho, Ana Cristina Feldner, Iandra Zaros, Antonio Eduardo Silva, Maria Lucia Ferraz. Poor response to hepatitis C treatment in elderly patients. Annals of Hepatology 2013; 12(3): 392 doi: 10.1016/S1665-2681(19)31001-4
|
22 |
Umberto Vespasiani-Gentilucci, Giovanni Galati, Paolo Gallo, Antonio De Vincentis, Elisabetta Riva, Antonio Picardi. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology 2015; 21(24): 7412-7426 doi: 10.3748/wjg.v21.i24.7412
|
23 |
Hideyuki Nomura, Yugo Miyagi, Hironori Tanimoto, Nobuyuki Yamashita, Kiyoaki Ito, Naohiko Masaki, Masashi Mizokami. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy. Journal of Gastroenterology and Hepatology 2012; 27(9): 1461 doi: 10.1111/j.1440-1746.2012.07171.x
|
24 |
Ataru Igarashi, Norihiro Furusyo, Eiichi Ogawa, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open 2019; 9(6): e023405 doi: 10.1136/bmjopen-2018-023405
|
25 |
Takahiro Azakami, C. Nelson Hayes, Hitomi Sezaki, Mariko Kobayashi, Norio Akuta, Fumitaka Suzuki, Hiromitsu Kumada, Hiromi Abe, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Hidenori Ochi, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama. Common genetic polymorphism of ITPA gene affects ribavirin‐induced anemia and effect of peg‐interferon plus ribavirin therapy. Journal of Medical Virology 2011; 83(6): 1048 doi: 10.1002/jmv.22069
|
26 |
Fabio Conti, Giovanni Vitale, Pietro Andreone. Treating hepatitis C in the elderly: the future is near?. Expert Opinion on Pharmacotherapy 2014; 15(14): 2019 doi: 10.1517/14656566.2014.945422
|
27 |
Jian-Wu Yu, Li-Jie Sun, Yong-Hua Zhao, Peng Kang, Bing-Zhu Yan. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment. International Journal of Infectious Diseases 2011; 15(11): e740 doi: 10.1016/j.ijid.2011.05.018
|
28 |
Norihiro Furusyo, Eiichi Ogawa, Masayuki Sudoh, Masayuki Murata, Takeshi Ihara, Takeo Hayashi, Hiroaki Ikezaki, Satoshi Hiramine, Haru Mukae, Kazuhiro Toyoda, Hiroaki Taniai, Kyoko Okada, Mosaburo Kainuma, Eiji Kajiwara, Jun Hayashi. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial. Journal of Hepatology 2012; 57(6): 1186 doi: 10.1016/j.jhep.2012.08.003
|
29 |
Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka. Role of <italic>IL28B</italic> genotype in older hepatitis C virus-infected patients. World Journal of Immunology 2013; 3(3): 54-61 doi: 10.5411/wji.v3.i3.54
|
30 |
Tomoo Miyauchi, Tatsuo Kanda, Fumio Imazeki, Rintaro Mikata, Akinobu Tawada, Makoto Arai, Keiichi Fujiwara, Shingo Nakamoto, Shuang Wu, Takeshi Tanaka, Tatsuo Miyamura, Michio Kimura, Yasuo Hirai, Motohide Takashi, Shigeru Mikami, Nobuyuki Sugiura, Yutaka Natsuki, Ryosaku Azemoto, Noriaki Suzuki, Osamu Yokosuka. Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatology International 2013; 7(1): 144 doi: 10.1007/s12072-012-9349-4
|
31 |
Vincenzo Boccaccio, Savino Bruno. Optimal management of patients with chronic hepatitis C and comorbidities. Liver International 2015; 35(s1): 35 doi: 10.1111/liv.12712
|
32 |
Sammy Saab, Justin Rheem, Vinay Sundaram. Hepatitis C Infection in the Elderly. Digestive Diseases and Sciences 2015; 60(11): 3170 doi: 10.1007/s10620-015-3717-6
|
33 |
Mosaburo Kainuma, Norihiro Furusyo, Koichi Azuma, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi. Pegylated interferon α‐2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Hepatology Research 2012; 42(1): 33 doi: 10.1111/j.1872-034X.2011.00907.x
|
34 |
E. Villa, C. Cammà, A. Di Leo, A. Karampatou, M. Enea, S. Gitto, V. Bernabucci, L. Losi, N. De Maria, B. Lei, A. Ferrari, R. Vukotic, P. Vignoli, M. Rendina, A. Francavilla. Peginterferon‐Α_2B plus ribavirin is more effective than peginterferon‐Α_2A plus ribavirin in menopausal women with chronic hepatitis C. Journal of Viral Hepatitis 2012; 19(9): 640 doi: 10.1111/j.1365-2893.2012.01593.x
|
35 |
Chun-Yen Lin, I-Shyan Sheen, Wen-Juei Jeng, Chang-Wen Huang, Chien-Hao Huang, Ji-Yih Chen. Patients younger than forty years old with hepatitis C virus genotype–1 chronic infection had treatment responses similar to genotype–2 infection and not related to interleukin–28B polymorphism. Annals of Hepatology 2013; 12(1): 62 doi: 10.1016/S1665-2681(19)31386-9
|
36 |
Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazuhiro Takahashi, Nobuhiko Higashi, Akira Kawano, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Research 2016; 136: 37 doi: 10.1016/j.antiviral.2016.10.012
|
37 |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α‐2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study. Journal of Gastroenterology and Hepatology 2012; 27(7): 1233 doi: 10.1111/j.1440-1746.2011.06965.x
|
38 |
Mohamed A Daw, Hana A Elasifer, Aghnaya A Dau, Mohamed Agnan. The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya. Virology Discovery 2013; 1(1): 3 doi: 10.7243/2052-6202-1-3
|
39 |
Miren Bravo, Jorge Simón, Irene González-Recio, Luis Alfonso Martinez-Cruz, Naroa Goikoetxea-Usandizaga, María Luz Martínez-Chantar. Magnesium and Liver Metabolism Through the Lifespan. Advances in Nutrition 2023; 14(4): 739 doi: 10.1016/j.advnut.2023.05.009
|